Value through Innovation19 April 2014

A Well-Balanced Pipeline

Boehringer Ingelheim has a rich pipeline showing a number of new molecular entities and a high share of products in late phase development. The company has brought a range of products from its own research & development to market. A number of these drugs have either achieved blockbuster status with annual sales exceeding one billion US dollars or have blockbuster potential.

Promising Drugs in our Pipeline

Compound* Clinical phase Indication
Therapeutic principle
Mode of action
Empagliflozin** Submitted Diabetes mellitus type II SGLT2-inhibition Inhibition of sodium dependent glucose transporter2
Empagliflozin+
Linagliptin**
Phase III Diabetes mellitus type II SGLT2-inhibition + DPP-4 inhibition Inhibition of glucose transporter-2 + Inhibition of dipeptidyl peptidase 4
Empagliflozin+
Metformin**
Phase III Diabetes mellitus type II SGLT2-inhibition+
biguanide
Inhibition of glucose transporter-2 + biguanide
Faldaprevir Submitted Hepatitis C Direct acting antiviral Oral HCV NS3/4A protease inhibitor
New Insulin Glargine** Submitted

Diabetes mellitus type I + II

Insulin analogue Insulin analogue
Nintedanib Submitted in EU Non-small cell lung cancer (NSCLC) Angiogenesis inhibition Triple angiokinase inhibitor, simultaneously blocks VEGFR, FGFR, PDGFR
Dabigatran etexilate Submitted Acute treatment and prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE) Oral anticoagulation Direct reversible thrombin inhibitor (DTI)
Olodaterol Submitted/ Approved
(EMA as Striverdi®)
Chronic obstructive pulmonary Disease (COPD) Anti-beta inhibition Long acting beta agonist (LABA)
Tiotropium Submitted Asthma Bronchodilatation Long Acting Muscarinic Antagonist (LAMA)
Afatinib Phase III Head and neck cancer Signal transduction inhibition Novel irreversible ErbB Family blocker
Nintedanib Phase III Ovarian cancer Angiogenesis inhibition Triple angiokinase inhibitor, simultaneously blocks VEGFR, FGFR, PDGFR
Nintedanib Phase III Idiopathic pulmonary fibrosis (IPF) Anti-fibrotic kinase inhibition Anti-fibrotic kinase inhibitor
Tiotropium+Olodaterol Phase III

Chronic obstructive pulmonary Disease(COPD)

Antimuscarinic inhibition/Anti-beta inhibition Long acting muscarinic agonist (LAMA)+Long acting beta agonist (LABA)
Volasertib Phase III Acute Myeloid Leukemia (AML)

Cell-cycle kinase inhibition

PLK-1 antagonist

* These are investigational agents; their safety and efficacy have not yet been established.
** In collaboration with Eli Lilly and Company

Status: February 2014

Successful Products from our own Research & Development

Product name
First launch
Active ingredient
Indication
Striverdi® 2014 Olodaterol Chronic obstructive pulmonary Disease (COPD)
Giotrif® /  Gilotrif™ 2013 Afatinib Non-small cell lung cancer (NSCLC)
Jentadueto® 2012 Linagliptin+Metformin Diabetes mellitus type II
Trajenta® 2011 Linagliptin Diabetes mellitus type II
Pradaxa®

2010

Dabigatran etexilate

Stroke prevention in atrial fibrillation

Twynsta® 2010 Telmisartan+Amlodipine Essential hypertension
Pradaxa® 2008 Dabigatran etexilate Prevention of venous thromboembolic events (VTE) in adults

Spiriva®
Respimat Soft Mist™ Inhaler

 

Spiriva®

2007

 

 


2002

Tiotropium

COPD

Micardis® 1998 Telmisartan Essential hypertension
Sifrol® / Mirapex® /


Mirapexin®

2006

 


1997

Pramipexole

Restless legs syndrome (RLS)

 

Parkinson's disease (PD)

Viramune® 1996 Nevirapine HIV/AIDS

Research & Development

Research & Development

Oncology Websites

No flash player detected. For optimized usage of this website your browser should support shockwave flash. For downloading see Macromedia Flash Player